Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115521) titled 'A single-center, open-label, Phase II study of Adebrelimab Injection in combination with albumin-paclitaxel and cisplatin for neoadjuvant treatment of resectable oral squamous cell carcinoma' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Hunan Cancer Hospital
Condition:
Oral squamous cell carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2025-12-31
Target Sample Size: The treatment of adebelimab combined with albumin-paclitaxel and cisplatin :30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn...